Anti-Mouse NKG2A/C/E – Purified in vivo GOLD™ Functional Grade

CHO transfected cells expressing the C57BL/6 allele of NKG2A and CD94

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone 20D5 recognizes an epitope on the mouse NKG2A, NKG2C, and NKG2E isoforms of the CD94/NKG2 heterodimer. DBA/2J mice are CD94-deficient and do not express CD94/NKG2 receptors.

NKG2A/C/E is expressed on NK cells, NKT cells, and activated CD8 T cells.

NKG2A/C/E antibody, clone 20D5, recognizes the NKG2A, NKG2C, and NKG2E isoforms (also known as CD159a, CD159c,m CD159e, respectively) of the NKG2 receptor, belonging to the C-type lectin-like family. NKG2 receptors are expressed at the cell surface as a heterodimer with CD94 and recognize the non-classical class I MHC-1 molecules HLA-E in humans and Qa-1 in mice^1-4. NKG2A/C/E are expressed on natural killer (NK) cells, NKT cells, and activated CD8 T cells^5-6. Engagement of NKG2A/CD94 transduces an inhibitory signal, blocking NK and CD8 T cell cytotoxicity and promoting self-tolerance⁷. In contrast, NKG2C/CD94 and NKGE/CD94 are activating receptors⁸ and bind with lower affinity to HLA-E⁹. Cancer cells frequently overexpress HLA-E to protect against NK/CD8 T cell killing, and blocking NKG2 receptors in mice promotes anti-tumor immunity and may enhance the cytotoxic potential of other therapeutic antibodies^10,11. The NKG2 receptor antibody monalizumab is currently in phase III clinical trials (INTERLINK-1) in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

150 kDa

Inhibitory activity via ITIMs

1. Vance R.E., et al. (1998) J. Exp. Med. 188:1841–1848
2. Braud VM, et al. (1998) Nature. 391(6669):795-9
3. Vance RE, et al. (1999) J Exp Med. 190(12):1801-1812
4. Brooks AG, et al. (1997) J Exp Med. 185(4):795-800
5. Gunturi A, Berg RE, Forman J. (2004) Immunol Res. 30(1):29-34
6. Bertone S, et al. (1999) Eur J Immunol. 29(1):23-9
7. Le Dréan E, et al. (1998) Eur J Immunol. 28(1):264-76
8. Lanier LL, et al. (1998) Immunity. 8(6):693-701
9. Kaiser BK, et al. (2005) J Immunol. 174(5):2878-84
10. André P, Denis C, Soulas C, et al. (2018) Cell. 175(7):1731-1743.e13
11. van Montfoort N, Borst L, Korrer MJ, et al. (2018) Cell. 175(7):1744-1755.e15